Supplementary Information

Supplementary Figure 1. Sample sizes across studies and ancestries

The left x-axis is showing VTE (venous thromboembolism) prevalence across the biobanks shaded by sampling strategy and the right x-axis is showing the number of VTE cases across the biobanks shaded by global ancestry labels.

UCLA=UCLA Precision Health Biobank; MGI=Michigan Genomics Initiative; BioMe=Mount Sinai BioMe Biobank; BioVU=Biorepository at Vanderbilt University; UKBB=United Kingdom Biobank; ESTBB=Estonia Biobank; GNH=East London Genes and Health; CKB=China Kadoorie Biobank; AFR= African ancestry; MID=Middle Eastern ancestry; AMR=Admixed American ancestry; EAS=East Asian ancestry; NFE=non-Finnish European; FIN=Finnish ancestry; SAS=South Asian ancestry



Supplementary Figure 2. Differential effect sizes between population-based and hospitalbased biobank meta-analyses

Meta-analysis in only population-based biobanks (UK Biobank, Estonian Biobank, Genes and Health, China Kadoorie Biobank) and hospital-based biobanks (UCLA Precision Health Biobank, Michigan Genomics Initiative, Mount Sinai BioMe Biobank, Biorepository at Vanderbilt University) was performed for index variants of genome wide significant loci for VTE. Only 4 loci have a p-value below 1x10⁻⁶ in both population-based and hospital-based meta-analyses. Overall, effect sizes are larger for population-based biobanks than hospital-based biobanks (slope=1.4, 95% CI 1.2-1.6).



Supplementary Figure 3. Variants with nominally significant heterogeneity across ancestries

Three variants (x-axis) had nominally (p-value < 0.05) significant heterogeneity across contributing ancestries. The estimated effect sizes (y-axis) shown here grouped by ancestry (NFE=non Finnish European; FIN=Finnish; AFR=African; ALL=combined ancestries in meta-analysis)



variants

Supplementary Figure 4. Ancestry specific locus rs112106699 near DHRS3

Summary statistics and forest plot for contributing cohorts and meta-analysis (in bold) at one genome wide significant variant. PoPS prioritized gene *DHRS3* is 4.4kilobases (kb) from the tag SNP and *VPS13D* is 51.4 kb away.

Freq=effect alelle frequency; Beta=estimated effect size from GWAS; BioMe_afr=Mount Sinai BioMe Biobank African ancestry; BioVU_afr=Biorepository at Vanderbilt University African ancestry; UKBB_afr=UK Biobank African ancestry; BioME_amr=Mount Sinai BioMe Biobank American ancestry; MGI_nfe=Michigan Genomics Initiative non-Finnish European ancestry; UKBB_nfe=UK Biobank non-Finnish European; UKBB_sas=UK Biobank South Asian ancestry

Biobank_Ancestry	Freq	Beta	P-value	
BioMe_afr	0.0906	0.5228	5.66e-03	
BioVU_afr	0.0599	0.3738	3.75e-03	
MGI_afr	0.0806	0.4379	2.62e-02	
UKBB_afr	0.0986	0.4687	3.29e-02	
BioMe_amr	0.0258	0.4987	1.14e-01	
MGI_nfe	0.0014	0.6274	2.59e-01	
UKBB_nfe	5e-04	0.8431	7.03e-02	
UKBB_sas	0.0031	1.4447	5.31e-01	$\leftarrow \rightarrow$
Summary	0.0045	0.4538	2.04e-08	-

-2 -1 0 1 2 Beta:log(Odds Rati

Supplementary Figure 5. Scatterplot of effect sizes between discovery and replication datasets



B.



a. Scatterplot of effect sizes with standard error bars for INVENT+MVP (y-axis) versus GBMI meta-analysis (x-axis). Intercept and slope shown are from York's regression (see STAR methods).

b. Scatterplot of effect sizes with standard error bars for INVENT+MVP (x-axis) versus GBMI meta-analysis without BioVU. This is a sensitivity analysis since the INVENT meta-analysis included eMERGE samples that could overlap with those of BioVU.

Supplementary Figure 6. Functional experiment pooling non-injected controls

Boxplot of time to occlusion in seconds (y-axis) for pooled uninjected controls (purple) and targeted genes (injected). P-values from wilcoxon rank sum test comparing all uninjected controls to each targeted gene are shown for each paired test. sgRNA=single guide RNA



Targeted locus

Supplementary Figure 7. Quantile-quantile plot (QQplot) for meta-analysis

Quantile-Quantile plot (QQplot) for meta-analysis p-values grouped and colored by minor allele frequency (MAF). Lambda at quantiles (0.001, 0.01, 0.1, 0.5, and 0.7) are calculated.



Supplementary Figure 8. Comparison of DEPICT and PoPs using a gold standard gene set Specificity (x-axis) and sensitivity (y-axis) for prioritization of 41 gold standard VTE genes using DEPICT (reds) and PoPS (blues). The multi-ancestry meta-analysis was used (ALL) as well as the non-Finnish European ancestry meta-analysis (NFE).



Supplementary Table 1: Previous VTE studies from the NHGRI-EBI GWAS catalog as of October 2021

Accompanying excel file

* GWAS for platelet thrombin activation

** GWAS for factor 5 plasma levels

Genome-wide association studies for Venous Thromboembolism in the GWAS Catalog (Buniello et al., 2019) as of June 2022. References: (Trégouët et al., 2009) (Germain et al., 2011) (Heit et al., 2012) (Greliche et al., 2013) (Tang et al., 2013) (Germain et al., 2015) (Hernandez et al., 2016) (Hinds et al., 2016) (Rühle et al., 2017) (Heit et al., 2017) (Klarin et al., 2017) (Thibord et al., 2019) (Klarin et al., 2019) (Deguchi et al., 2020) (Rodriguez et al., 2020) (Mateos et al., 2020) (Herrera-Rivero et al., 2021)

Supplementary Table 2. Gold standard coagulation genes with associations with Venous Thromboembolism

Genes known to be associated with blood coagulation and/or platelet disorder functional assays and human genetics assays known from the literature(Downes et al., 2019). The list is filtered for genes that are not duplicated in zebrafish for experimental purposes. Notably, the landscape of gold standard genes is slightly different from the genes identified via genome wide association studies (GWASs). Accompanying excel file

* Also associated with platelet disorder

Supplementary Table 3. 38 genome-wide significant loci from GBMI meta-anlaysis

Accompanying excel file

31 lead SNPs are within 500 kb of a variant previously reported in GWAS or sequencing studies, resulting in 9 potentially novel associations

Supplementary Table 4. Meta-analysis of replication and leave BioVU out GBMI meta-analysis Accompanying excel file

Of the 37 markers available for replication in the INVENT+MVP meta-analysis, 34 are genome-wide significant $(5x10^{-8})$ with inverse variance based meta-analysis and two sided p-value. This sensitivity analysis accounts for possible inclusion of samples in both the INVENT+MVP analysis and the GBMI meta-analysis with BioVU included.

Supplementary Table 5. KEGG Pathways

Accompanying excel file

Kyoto Encyclopedia of Genes and Genomes (KEGG, Human cell signaling and metabolic pathways version 2021) enriched in 38 prioritized genes from genome-wide significant loci. Adjusted p-value is using Benjamini-Hochberg method for multiple hypothesis testing.

Supplementary Table 6. Gene Ontology (GO) Biological Processes

Accompanying excel file

Gene Ontology (GO) terms for biological processes (2021 version) enriched in 38 prioritized genes from genome-wide significant loci. Adjusted p-value is using Benjamini-Hochberg method for multiple hypothesis testing.

Supplementary Table 7. Gene Ontology (GO) Molecular Function

Accompanying excel file

Gene Ontology (GO) terms for biological processes (2018 version) enriched in 38 prioritized genes from genome-wide significant loci. Adjusted p-value is using Benjamini-Hochberg method for multiple hypothesis testing.

Supplementary Table 8: Case and control definitions used in analysis plan provided to participating biobanks

Note, the replication cohort INVENT defined also included cases from self-report which were interview with a trained nurse to confirm diagnosis(Klarin et al., 2017).

Subset	ICD codes	Description
		Hospitalization for ICD-10 Code I80.1 or I80.2 - phlebitis and thrombophlebitis of the femoral vein or other deep vessels of lower extremities;
		Hospitalization for ICD-10 Code I82.2 - embolism and thrombosis of vena cava;
cases inclusion (ICD10)	180.1, 180.2, 182.2 , 126.0, 126.9	Hospitalization for ICD-10 Code I26.0 or I26.9 - pulmonary embolism with or without acute cor pulmonale;
cases inclusion (ICD9)	451.11, 453.40, 453.2, 453.77, 453.87, 415.1	
		Hospitalization for OPCS-4 Procedures Codes L79.1 or L90.2 - open venous thrombectomy of lower limb vein or inferior vena cava filter insertion.
cases inclusion		Open venous thrombectomy of lower limb vein or inferior vena cava filter
(OPCS codes)	L79.1 or L90.2	insertion.
controls exclusion (ICD10)	181, 182.0, 180.0, 180.3, 180.8, 180.9, D68	portal vein thrombosis (I81), Budd-Chiari syndrome (I82.0), superficial or unclear site of thrombophlebitis (I80.0, I80.3, I80.8, I80.9), or known coagulation defects (D68).
controls exclusion (ICD9)	452,453.0,451. 0,451.89,451.9, 286	

Supplementary Table 9: Effective sample sizes across ancestries

UCLA=UCLA Precision Health Biobank; MGI=Michigan Genomics Initiative; BioMe=Mount Sinai BioMe Biobank; BioVU=Biorepository at Vanderbilt University; UKBB=United Kingdom Biobank; ESTBB=Estonia Biobank; GNH=East London Genes and Health; CKB=China Kadoorie Biobank

Ancestries	Cohorts	Cases	Controls	Effective Sample Size
African	BioMe, BioVU, UKB, UCLA	1,466	31,042	5,477
Admixed American	BioMe, UCLA	1,037	12,479	3,772
East Asian	CKB, UCLA	193	77,462	741
Finnish	FinnGen	9,176	209,616	NA
Non-Finnish European	BioMe, BioVU, EstBB, MGI, UCLA, UKB	15,970	681,106	61,678
South Asian	GNH, UKB	145	23,585	576
Total		27,987	1,035,290	107,409

Supplementary Table 10. Sample size for VTE in each cohort by ancestry, sexes combined

UCLA=UCLA Precision Health Biobank; MGI=Michigan Genomics Initiative; BioMe=Mount Sinai BioMe Biobank; BioVU=Biorepository at Vanderbilt University; UKBB=United Kingdom Biobank; ESTBB=Estonia Biobank; GNH=East London Genes and Health; CKB=China Kadoorie Biobank; AFR= African ancestry; MID=Middle Eastern ancestry; AMR=Admixed American ancestry; EAS=East Asian ancestry; NFE=non-Finnish European; FIN=Finnish ancestry; SAS=South Asian ancestry

Biobank	Ancestry	Case	Control
BioMe	afr	477	6287
BioMe	nfe	253	8903
BioMe	amr	494	8647
BioVU	afr	434	14295
BioVU	nfe	2295	65621
СКВ	eas	61	75294
ESTBB	nfe	1177	131802
FinnGen	fin	9176	209616
GNH	sas	84	14793
MGI	afr	231	2935
MGI	nfe	2999	47845
UCLA	afr	195	1031
UCLA	amr	543	3832
UCLA	eas	132	2168
UCLA	nfe	1503	15138
UKBB	afr	129	6494
UKBB	sas	61	8792
UKBB	nfe	7743	411797
Total		27987	1035290

Supplementary Table 11. Effective Sample Sizes for each cohort, by ancestries, by sex Accompanying excel file

Effect sample sizes for each cohort, each ancestry group for both sexes combined and stratified by sex. Sample names with "leave" are for each leave one biobank out meta-analysis performed. UCLA=UCLA Precision Health Biobank; MGI=Michigan Genomics Initiative; BioMe=Mount Sinai BioMe Biobank; BioVU=Biorepository at Vanderbilt University; UKBB=United Kingdom Biobank; ESTBB=Estonia Biobank; GNH=East London Genes and Health; CKB=China Kadoorie Biobank; AFR= African ancestry; MID=Middle Eastern ancestry; AMR=Admixed American ancestry; EAS=East Asian ancestry; NFE=non-Finnish European; FIN=Finnish ancestry; SAS=South Asian ancestry

Supplementary Table 12. Replication cohort sample sizes by ancestry groups

INVENT=International Network on Venous Thrombosis MVP=Million Veteran Program

Cohort and ancestry	Cases	Controls
INVENT European	15,572	113,430
INVENT African	799	14,353
MVP European	18,952	411,746
MVP African	5,521	103,791
MVP Hispanic	1,188	45,634
Total	42,032	688,954

Supplementary Table 13. Genetic instruments for two-sample Mendelian Randomization Accompanying excel file

18 single nucleotide polymorphisms (SNPs) selected as genetic instruments. EAF=effect allele frequency; SE=standard error

Supplementary Table 14. Efficient single guide RNAs (sgRNA) for CRISPR/Cas9 mediated genome editing.

Accompanying excel file

Genes of interest identified for validation in zebrafish and the corresponding sgRNAs used for CRISPR/Cas9 genome editing knockdown.

Supplementary References

Buniello, A., MacArthur, J.A.L., Cerezo, M., Harris, L.W., Hayhurst, J., Malangone, C., McMahon, A., Morales, J., Mountjoy, E., Sollis, E., et al. (2019). The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. *47*, D1005–D1012. https://doi.org/10.1093/nar/gky1120.

Deguchi, H., Shukla, M., Hayat, M., Torkamani, A., Elias, D.J., and Griffin, J.H. (2020). Novel exomic rare variants associated with venous thrombosis. Br. J. Haematol. *190*, 783–786. https://doi.org/10.1111/bjh.16613.

Downes, K., Megy, K., Duarte, D., Vries, M., Gebhart, J., Hofer, S., Shamardina, O., Deevi, S.V.V., Stephens, J., Mapeta, R., et al. (2019). Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. Blood *134*, 2082–2091. https://doi.org/10.1182/blood.2018891192.

Germain, M., Saut, N., Greliche, N., Dina, C., Lambert, J.-C., Perret, C., Cohen, W., Oudot-Mellakh, T., Antoni, G., Alessi, M.-C., et al. (2011). Genetics of venous thrombosis: insights from a new genome wide association study. PLoS One *6*, e25581. https://doi.org/10.1371/journal.pone.0025581.

Germain, M., Chasman, D.I., de Haan, H., Tang, W., Lindström, S., Weng, L.-C., de Andrade, M., de Visser, M.C.H., Wiggins, K.L., Suchon, P., et al. (2015). Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism. Am. J. Hum. Genet. *96*, 532–542. https://doi.org/10.1016/j.ajhg.2015.01.019.

Greliche, N., Germain, M., Lambert, J.-C., Cohen, W., Bertrand, M., Dupuis, A.-M., Letenneur, L., Lathrop, M., Amouyel, P., Morange, P.-E., et al. (2013). A genome-wide search for common SNP x SNP interactions on the risk of venous thrombosis. BMC Med. Genet. *14*, 36. https://doi.org/10.1186/1471-2350-14-36.

Heit, J.A., Armasu, S.M., Asmann, Y.W., Cunningham, J.M., Matsumoto, M.E., Petterson, T.M., and De Andrade, M. (2012). A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q. J. Thromb. Haemost. *10*, 1521–1531. https://doi.org/10.1111/j.1538-7836.2012.04810.x.

Heit, J.A., Armasu, S.M., McCauley, B.M., Kullo, I.J., Sicotte, H., Pathak, J., Chute, C.G., Gottesman, O., Bottinger, E.P., Denny, J.C., et al. (2017). Identification of unique venous thromboembolism-susceptibility variants in African-Americans. Thromb. Haemost. *117*, 758–768. https://doi.org/10.1160/TH16-08-0652.

Hernandez, W., Gamazon, E.R., Smithberger, E., O'Brien, T.J., Harralson, A.F., Tuck, M., Barbour, A., Kittles, R.A., Cavallari, L.H., and Perera, M.A. (2016). Novel genetic predictors of venous thromboembolism risk in African Americans. Blood *127*, 1923–1929. https://doi.org/10.1182/blood-2015-09-668525.

Herrera-Rivero, M., Stoll, M., Hegenbarth, J.-C., Rühle, F., Limperger, V., Junker, R., Franke, A., Hoffmann, P., Shneyder, M., Stach, M., et al. (2021). Single- and Multimarker Genome-Wide Scans Evidence Novel Genetic Risk Modifiers for Venous Thromboembolism. Thromb.

Haemost. 121, 1169-1180. https://doi.org/10.1055/s-0041-1723988.

Hinds, D.A., Buil, A., Ziemek, D., Martinez-Perez, A., Malik, R., Folkersen, L., Germain, M., Mälarstig, A., Brown, A., Soria, J.M., et al. (2016). Genome-wide association analysis of self-reported events in 6135 individuals and 252 827 controls identifies 8 loci associated with thrombosis. Hum. Mol. Genet. *25*, 1867–1874. https://doi.org/10.1093/hmg/ddw037.

Klarin, D., Emdin, C.A., Natarajan, P., Conrad, M.F., INVENT Consortium, and Kathiresan, S. (2017). Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor. Circ. Cardiovasc. Genet. *10*. https://doi.org/10.1161/CIRCGENETICS.116.001643.

Klarin, D., Busenkell, E., Judy, R., Lynch, J., Levin, M., Haessler, J., Aragam, K., Chaffin, M., Haas, M., Lindström, S., et al. (2019). Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat. Genet. *51*, 1574–1579. https://doi.org/10.1038/s41588-019-0519-3.

Mateos, M.K., Tulstrup, M., Quinn, M.C., Tuckuviene, R., Marshall, G.M., Gupta, R., Mayoh, C., Wolthers, B.O., Barbaro, P.M., Ruud, E., et al. (2020). Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian Children. Cancers *12*. https://doi.org/10.3390/cancers12051285.

Rodriguez, B.A.T., Bhan, A., Beswick, A., Elwood, P.C., Niiranen, T.J., Salomaa, V., FinnGen Study, Trégouët, D.-A., Morange, P.-E., Civelek, M., et al. (2020). A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling. Am. J. Hum. Genet. *107*, 211–221. https://doi.org/10.1016/j.ajhg.2020.06.008.

Rühle, F., Witten, A., Barysenka, A., Huge, A., Arning, A., Heller, C., Krümpel, A., Mesters, R., Franke, A., Lieb, W., et al. (2017). Rare genetic variants in SMAP1, B3GAT2, and RIMS1 contribute to pediatric venous thromboembolism. Blood *129*, 783–790. https://doi.org/10.1182/blood-2016-07-728840.

Tang, W., Teichert, M., Chasman, D.I., Heit, J.A., Morange, P.-E., Li, G., Pankratz, N., Leebeek, F.W., Paré, G., de Andrade, M., et al. (2013). A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Genet. Epidemiol. *37*, 512–521. https://doi.org/10.1002/gepi.21731.

Thibord, F., Hardy, L., Ibrahim-Kosta, M., Saut, N., Pulcrano-Nicolas, A.-S., Goumidi, L., Civelek, M., Eriksson, P., Deleuze, J.-F., Le Goff, W., et al. (2019). A Genome Wide Association Study on plasma FV levels identified PLXDC2 as a new modifier of the coagulation process. J. Thromb. Haemost. *17*, 1808–1814. https://doi.org/10.1111/jth.14562.

Trégouët, D.-A., Heath, S., Saut, N., Biron-Andreani, C., Schved, J.-F., Pernod, G., Galan, P., Drouet, L., Zelenika, D., Juhan-Vague, I., et al. (2009). Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood *113*, 5298–5303. https://doi.org/10.1182/blood-2008-11-190389.

GBMI Membership

Wei Zhou^{1,2,3}, Masahiro Kanai^{1,2,3,4,5}, Kuan-Han H Wu⁶, Humaira Rasheed^{7,8,9}, Kristin Tsuo^{1,2,3}, Jibril B Hirbo^{10,11}, Ying Wang^{1,2,3}, Arjun Bhattacharya¹², Huiling Zhao⁹, Shinichi Namba⁵, Ida Surakka¹³, Brooke N Wolford^{6,7}, Valeria Lo Faro^{14,15,16}, Esteban A Lopera- Maya¹⁷, Kristi Läll¹⁸, Marie-Julie Favé¹⁹, Sinéad B Chapman^{2,3}, Juha Karjalainen^{1,2,3,20}, Mitja Kurki^{1,2,3,20}, Maasha Mutaamba^{1,2,3,20}, Juulia Partanen²⁰, Ben M Brumpton^{7,21,22}, Sameer Chavan²³, Tzu-Ting Chen²⁴, Michelle Daya²³, Yi Ding^{12,25}, Yen-Chen A Feng^{26,27}, Christopher R Gignoux²³, Sarah E Graham¹³, Whitney E Hornsby¹³, Nathan Ingold^{28,29}, Ruth Johnson^{12,30}, Triin Laisk¹⁸, Kuang Lin³¹, Jun Lv³², Iona Y Millwood^{31,33}, Priit Palta^{18,20}, Anita Pandit³⁴, Michael H Preuss³⁵, Unnur Thorsteinsdottir³⁶, Jasmina Uzunovic¹⁹, Matthew Zawistowski³⁴, Xue Zhong^{10,11}, Archie Campbell³⁷, Kristy Crooks²³, Geertruida H de Bock³⁸, Nicholas J Douville^{39,40}, Sarah Finer⁴¹, Lars G Fritsche³⁴, Christopher J Griffiths⁴¹, Yu Guo⁴², Karen A Hunt⁴³, Takahiro Konuma^{5,44}, Riccardo E Marioni³⁷, Jansonius Nomdo¹⁴, Snehal Patil³⁴, Nicholas Rafaels²³, Anne Richmond⁴⁵, Jonathan A Shortt²³, Peter Straub^{10,11}, Ran Tao¹¹, Brett Vanderwerff³⁴, Kathleen C Barnes²³, Marike Boezen³⁸, Zhengming Chen^{31,33}, Chia-Yen Chen⁴⁶, Judy Cho³⁵, George Davey Smith^{9,47}, Hilary K Finucane^{1,2,3}, Lude Franke¹⁷, Eric R Gamazon^{10,11,48}, Andrea Ganna^{1,2,20}, Tom R Gaunt⁹, Tian Ge^{27,49}, Hailiang Huang^{1,2}, Jennifer Huffman⁵⁰, Jukka T. Koskela²⁰, Clara Lajonchere^{51,52}, Matthew H Law^{28,29}, Liming Li³², Cecilia M Lindgren⁵³, Ruth JF Loos^{35,54}, Stuart MacGregor²⁸, Koichi Matsuda⁵⁵, Catherine M Olsen²⁸, David J Porteous³⁷, Jordan A Shavit⁵⁶, Harold Snieder³⁸, Richard C Trembath⁵⁷, Judith M Vonk³⁸, David Whiteman²⁸, Stephen J Wicks²³, Cisca Wijmenga¹⁷, John Wright⁵⁸, Jie Zheng⁹, Xiang Zhou³⁴, Philip Awadalla^{19,59}, Michael Boehnke³⁴, Nancy J Cox^{10,11}, Daniel H Geschwind^{51,60,61}, Caroline Hayward⁴⁵, Kristian Hveem^{7,21}, Eimear E Kenny⁶², Yen-Feng Lin^{24,63,64}, Reedik Mägi¹⁸, Hilary C Martin⁶⁵, Sarah E Medland²⁸, Yukinori Okada^{5,66,67,68,69}, Aarno V Palotie^{1,2,20}, Bogdan Pasaniuc^{12,25,51,60,70}, Serena Sanna^{17,71}, Jordan W Smoller²⁷, Kari Stefansson³⁶, David A van Heel⁴³, Robin G Walters^{31,33}, Sebastian Zöllner³⁴, Biobank Japan, BioMe, BioVU, Canadian Partnership for Tomorrow's Health/Ontario Health Study, China Kadoorie Biobank Collaborative Group, Colorado Center for Personalized Medicine, deCODE Genetics, Estonian Biobank, FinnGen, Generation Scotland, Genes & Health, LifeLines, Mass General Brigham Biobank, Michigan Genomics Initiative, QIMR Berghofer Biobank, Taiwan Biobank, The HUNT Study, UCLA ATLAS Community Health Initiative, UK Biobank, Alicia R Martin^{1,2,3}, Cristen J Willer^{6,13,72*}, Mark J Daly^{1,2,3,20*}, Benjamin M Neale^{1,2,3*}

‡Deceased

*These authors jointly supervised this work

¹Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA, ²Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA, ³Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA, ⁴Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA, ⁵Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita 565-0871, Japan, ⁶Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA, ⁷K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway, ⁸Division of Medicine and

Laboratory Sciences, University of Oslo, Norway, ⁹MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Bristol, UK, ¹⁰Department of Medicine, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA, ¹¹Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA, ¹²Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA, ¹³Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, USA, ¹⁴University of Groningen, UMCG, Department of Ophthalmology, Groningen, the Netherlands, ¹⁵Department of Clinical Genetics, Amsterdam University Medical Center (AMC), Amsterdam, the Netherlands, ¹⁶Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden, ¹⁷University of Groningen, UMCG, Department of Genetics, Groningen, the Netherlands, ¹⁸Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia, ¹⁹Ontario Institute for Cancer Research, Toronto, ON, Canada, ²⁰Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland, ²¹HUNT Research Centre, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Levanger, Norway, ²²Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, ²³University of Colorado - Anschutz Medical Campus, Aurora, CO, USA, ²⁴Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan, ²⁵Bioinformatics Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA, USA, ²⁶Division of Biostatistics, Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taiwan, ²⁷Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA, ²⁸QIMR Berghofer Medical Research Institute, Brisbane, Australia, ²⁹Faculty of Health, School of Biomedical Sciences, Queensland University of Technology, Australia, ³⁰Department of Computer Science, University of California, Los Angeles, Los Angeles, CA, USA, ³¹Nuffield Department of Population Health, University of Oxford, Oxford, UK, ³²Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China, ³³MRC Population Health Research Unit, University of Oxford, Oxford, UK, ³⁴Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, USA, ³⁵The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA, ³⁶deCODE Genetics/Amgen inc., 101, Revkjavik, Iceland, ³⁷Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK, ³⁸University of Groningen, UMCG, Department of Epidemiology, Groningen, the Netherlands, ³⁹Department of Anesthesiology, Michigan Medicine, Ann Arbor, MI, USA, ⁴⁰Institute of Healthcare Policy & Innovation, University of Michigan, Ann Arbor, MI, USA, ⁴¹Wolfson Institute of Population Health, Queen Mary University of London, London, UK, ⁴²Chinese Academy of Medical Sciences, Beijing, China, ⁴³Blizard Institute, Queen Mary University of London, London, UK, ⁴⁴Central Pharmaceutical Research Institute, JAPAN TOBACCO INC., Takatsuki 569-1125, Japan, ⁴⁵Medical Research Council Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK, ⁴⁶Biogen, Cambridge, MA, USA, ⁴⁷NIHR Bristol Biomedical Research Centre, Bristol, UK, ⁴⁸MRC Epidemiology Unit, University of Cambridge, Cambridge, UK, ⁴⁹Center for Precision Psychiatry, Massachusetts General Hospital, Boston, MA, USA, ⁵⁰Centre for Population Genomics, VA Boston Healthcare System, Boston, MA, USA, ⁵¹Institute of Precision Health, University of California, Los Angeles, Los Angeles, CA, USA, ⁵²Program in Neurogenetics,

Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA, ⁵³Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK, ⁵⁴Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Medicine and Health Sciences, University of Copenhagen, Copenhagen, Denmark, ⁵⁵Department of Computational Biology and Medical Sciences, Graduate school of Frontier Sciences, The University of Tokyo, Tokyo, Japan, ⁵⁶University of Michigan, Department of Pediatrics, Ann Arbor MI 48109, ⁵⁷School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK, ⁵⁸Bradford Institute for Health Research, Bradford Teaching Hospitals National Health Service (NHS) Foundation Trust, Bradford, UK, ⁵⁹Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada, ⁶⁰Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA, ⁶¹Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA, ⁶²Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA, ⁶³Department of Public Health & Medical Humanities, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ⁶⁴Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ⁶⁵Medical and Population Genomics, Wellcome Sanger Institute, Hinxton, UK, ⁶⁶Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita 565-0871, Japan, ⁶⁷Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita 565-0871, Japan, ⁶⁸Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, ⁶⁹Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita 565-0871, Japan, ⁷⁰Department of Computational Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA, ⁷¹Institute for Genetics and Biomedical Research (IRGB), National Research Council (CNR), Cagliari, Italy, ⁷²Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA